0001193125-26-171887
SEC filingSight Sciences received a final judgment of $55.4 million in damages and a 10% ongoing royalty for patent infringement by Alcon, subject to appeal.
On April 22, 2026, Sight Sciences received notification that the U.S. District Court for the District of Delaware entered final judgment in its patent infringement case against Alcon. The judgment upholds the jury's findings that Alcon willfully infringed three Sight Sciences patents related to the Hydrus Microstent. The total monetary award of $55.4 million includes past damages, supplemental damages, and interest through April 17, 2026. Additionally, an ongoing royalty of 10% of Hydrus revenue is awarded until the last patent expires. However, the judgment is subject to appeal by Alcon, and no payments will be received until appeals are exhausted or the time to appeal passes. During any appeal, interest and royalties continue to accrue. A potential risk exists if Alcon's ex parte reexamination proceedings result in an adverse ruling before the litigation judgment becomes final and non-appealable, which could negatively affect collection. Investors should monitor the appeal process and reexamination outcomes.